<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:section/paragraph)	n/a
For commercial reagents, provide supplier	Not applicable.	N/A
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided:section/paragraph)	n/a
Cell lines: Provide species information, strain.	Not applicable.	N/A
Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		
Primary cultures: Provide species, strain, sex of	Not applicable.	N/A
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided:section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	Not applicable.	N/A
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the	Not applicable.	N/A
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number	Not applicable.	N/A
in repository (where relevant) OR RRID		

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Not applicable.	N/A
Microbes: provide species and strain, unique accession number if available, and source	Not applicable.	N/A

Human research participants	Yes (indicate where provided:section/paragraph)	n/a
Identify authority granting ethics approval(IRB or	Ethical Statement/Paragraph 1	-
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent	Methods/Paragraph 1	-
obtained from study participants.		
Report on age and sex for all study participants.	Methods/Paragraph 1	-

Design

Studyprotocol	Yes (indicate where provided:section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	Not applicable.	N /A
Laboratoryprotocol	Yes (indicate where provided:section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	Not applicable.	N/A
Experimental study design (statistics details)	Yes (indicate where provided:section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	Not applicable.	N/A
Randomisation	Not applicable.	N/A
Blinding	Not applicable.	N/A
Inclusion/exclusion criteria	Not applicable.	N/A
Sample definition and in-laboratory replication	Yes (indicate where provided:section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Not applicable.	N/A
Define whether data describe technical or biological replicates	Not applicable.	N/A
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Ethical Statement/Paragraph 1	-
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Ethical Statement/Paragraph 1	-
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Ethical Statement/Paragraph 1	-
Dual Use Research of Concern (DURC)	Yes (indicate where provided:section/paragraph)	n/a
If study is subject to dual use research ofconcern, statethe authority granting approval and reference number for the regulatory approval	Not applicable.	N/A

<u>Analysis</u>

Attrition	Yes (indicate where provided:section/paragraph)	n/a
State if sample or data point from the analysis is	Methods/ Paragraph 2	-
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided:section/paragraph)	n/a
Describestatistical tests used and justify choice of	Methods/Statistical method	-
tests.		1

Data Availability	Yes (indicate where provided:section/paragraph)	n/a
State whether newly created datasets are available,	Not applicable.	N/A
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession	Not applicable.	N/A
number in repository or DOI or URL.		
If publicly available data are reused, provide	Not applicable.	N/A
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided:section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	Not applicable.	N/A
If code is publicly available, provide accession	Not applicable.	N/A
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		-
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	-
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article Information: http://dx.doi.org/10.21037/jtd-20-2666